Loading
A phase 2 trial of toripalimab and sacituzumab tirumotecan in lung cancer, run by Shaodong Hong, not yet recruiting.
Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLC is a phase 2, interventional study registered as NCT07819578 by Shaodong Hong, with a registry enrolment figure of 30 participants, started 2026-10-01 and due to reach its primary completion in 2028-12-01. Interventions recorded: Toripalimab; Sacituzumab Tirumotecan (SKB264). Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Pathological Complete Response (pCR) Rate. Lung eligibility wording from the registry: "* Histologically/cytologically confirmed, treatment-naive, resectable or potentially resectable NSCLC: stage II-IIIA and selected IIIB (T3N2, T4N2) per IASLC/UICC TNM 9th edition". No results are recorded here; the registry entry is the source.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Lung cancer trials open today (registry snapshot), Antibody-drug conjugate (ADC) and the tag lung-deep-dive.
Shares Toripalimab, Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Toripalimab, Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Lung cancer trials open today (registry snapshot), Antibody-drug conjugate (ADC) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.